BCPC

Balchem reported record Q3 2026 sales of $291 million with 8.6% year-over-year growth. The company is expanding its science-backed specialty ingredients like VitaCholine and K2VITAL DELTA from infant nutrition into adult cognitive and cardiovascular markets.

Proprietary encapsulation technology is driving adoption in animal nutrition, while a high-margin product mix is fueling segment profitability. The company achieved its 29th consecutive quarter of year-over-year adjusted EBITDA growth.

Balchem Corporation reported record third quarter 2026 results with net sales of $290.7 million (up 8.6% YoY), net earnings of $46.7 million (up 16.0% YoY), and adjusted EBITDA of $80.3 million (up 12.4% YoY). All three business segments showed healthy growth, with the company maintaining a strong balance sheet and executing strategic growth initiatives including $127 million in share repurchases over the trailing twelve months.

Balchem Corporation announced a conference call scheduled for October 23, 2026, at 11:00 AM ET to discuss third quarter 2026 financial results. CEO Ted Harris and CFO Martin Bengtsson will host the call, with results to be published prior to market opening. The call will be available via phone and webcast.